Aarti Industries has signed a 10-year manufacturing and supply agreement with a global specialty chemical partner. The deal offers a revenue potential of Rs 1,500 crore, supported by a planned CAPEX of under $25 million. The dedicated manufacturing facility is expected to be commissioned by FY2028-29, enhancing long-term revenue visibility for the company.
Aarti Industries Secures Rs 1,500 Crore Long-Term Manufacturing Deal
Revenue Potential: Rs 1,500 crore; Estimated CAPEX: Under $25 million.
Reader Takeaway: This 10-year agreement brings a new global customer and predictable long-term revenue via efficient asset utilization.
What just happened
Aarti Industries Limited (AIL) has entered into a strategic, 10-year manufacturing and supply agreement with an undisclosed global specialty chemical firm. The partnership involves AIL setting up a dedicated manufacturing facility in India to produce a high-performance chemical using the partner's proprietary process technology.
Why this matters
This deal strengthens AIL’s position as a preferred partner for global chemical majors looking to manufacture in India. By leveraging AIL's process engineering expertise alongside proprietary tech, the company secures a capital-efficient revenue stream. The project is estimated to contribute approximately Rs 1,500 crore (US$150 million) to the top line over the contract term.
Operational Roadmap
The company is committing less than US$25 million in capital expenditure for the new facility. AIL will oversee the setup and operation, with commercial production slated to commence in FY2028–29, subject to regulatory clearances.
Management Commentary
MD and CEO Suyog Kotecha highlighted that the agreement adds a significant new global client to their portfolio. He stated that the partnership reflects the market's trust in AIL's capability to manage dedicated assets to global standards, providing a stable, long-term growth platform.
Risks to watch
Success relies on the timely receipt of regulatory approvals and strict adherence to the project timeline. Any delays in commissioning the facility in FY2028-29 could impact the projected revenue recognition schedule.
What to track next
Investors should look for updates on the land acquisition or facility construction progress, as well as any further disclosures regarding the specific chemical product segments involved.